Marc Koska
Most organisations know what the safer option is. They choose the familiar one anyway. When procurement systems, regulatory bodies, and established manufacturers benefit from the status quo, a better solution can sit unused for decades.
Scaling a proven innovation to global adoption requires more than good design: Marc Koska OBE, inventor of the K1 auto-disable syringe and Schwab Foundation Social Entrepreneur of the Year, spent three decades navigating WHO policy, manufacturing norms, and public behaviour to turn a single design insight into a global standard.
Full Profile
Why organisations work with Marc Koska
- He built the commercial case for a life-saving innovation from first principles; price parity, existing tooling, no retraining required, so that institutional resistance had no rational hiding place. Few innovators have that level of strategic discipline documented at scale.
- His 2008 India campaign reached 508 million people and triggered a government mandate within months. That is a documented playbook for moving from public awareness to policy change at national scale, directly applicable to any organisation trying to shift entrenched behaviour.
- He holds The Economist Innovation Award for Social and Economic Innovation, a Schwab Foundation Social Entrepreneur of the Year designation, and an OBE; the kind of external validation that makes a business case credible in front of conservative institutional and government audiences.
- His ApiJect work, backed by US Department of Defense and HHS funding for pandemic response infrastructure, demonstrates how the same innovation principles apply to supply chain resilience and emergency preparedness.
- Unlike most entrepreneurship narratives, his story has a documented endpoint: a 2015 WHO global policy mandate requiring auto-disable syringes across the therapeutic sector, 30 years after the K1 was first conceived.
Biography highlights
- Inventor of the K1 auto-disable syringe: locks after a single use, licensed to 14 global manufacturers, credited with saving over 10 million lives
- OBE awarded 2006 for contribution to global healthcare
- The Economist Innovation Award for Social and Economic Innovation; Schwab Foundation Social Entrepreneur of the Year 2015, World Economic Forum network
- Ashoka Fellow 2017; honorary doctorates from the University of Sussex and Brighton University
- Founder of Star Syringe (1996) and The SafePoint Trust, the UK registered charity whose advocacy helped drive the 2015 WHO global injection safety mandate
- Speaker at TED, Google Zeitgeist, Intelligence Squared, and the World Economic Forum
Biography
The K1 syringe was engineered to be as cheap as the one it replaced, to run on the same factory tooling, and to lock after a single use. Marc Koska designed it that way deliberately, because he understood that a safer product priced as a premium would never reach the patients who needed it most.
Koska founded Star Syringe in 1996 to license the technology, and The SafePoint Trust as a registered UK charity to run commercial and advocacy strategies in parallel. His 2008 India campaign, press conferences in 14 cities, television, radio, and cinema, reached 508 million people and led the Indian Health Ministry to mandate auto-disable syringes across government hospitals. The WHO followed with a global injection safety mandate in 2015.
The Economist recognised his work with its Innovation Award for Social and Economic Innovation. The Schwab Foundation named him Social Entrepreneur of the Year in 2015, integrating him into the World Economic Forum network. An OBE for services to global healthcare, an Ashoka Fellowship, and honorary doctorates from the University of Sussex and Brighton University reflect the breadth of institutions that have validated his contribution. His TED talks and appearances at Google Zeitgeist have brought the commercial logic of his approach to audiences well beyond the health sector.
His more recent work through ApiJect, a blow-fill-seal prefilled injector developed with US Department of Defense and HHS backing for pandemic response, applies the same principle to national supply chain resilience: remove the systemic barriers that allow an inferior standard to persist. For leadership teams thinking about scaling innovation through complex regulatory environments, his three-decade arc from design brief to global standard is among the most instructive available.
Key speaking topics
- Scaling innovation from invention to global adoption
- Navigating policy, procurement, and regulatory barriers
- Social entrepreneurship and mission-driven commercial design
- Stakeholder mobilisation and behaviour change at scale
- Public health risk and injection safety
- Pandemic preparedness and supply chain resilience
Ideal for
- Senior leadership teams and boards navigating innovation adoption in regulated or institutionally resistant industries
- CEOs and commercial directors seeking a case study in displacing entrenched incumbents with a commercially competitive alternative
- Public health, pharmaceutical, and medical device executives responsible for global supply chain and safety standards
- Conference audiences focused on social entrepreneurship, purpose-driven business, and systemic change
Audience outcomes
- A framework for identifying where institutional inertia – rather than product quality – is blocking innovation adoption
- Practical understanding of how to design innovations for price parity and manufacturing compatibility from the outset
- Insight into how multi-stakeholder campaigns can translate public awareness into government policy change
- A case study in running commercial and advocacy strategies in parallel without mission drift
- A concrete example of what it takes to move a proven innovation from proof of concept to a WHO-mandated global standard